|
62th Annual Meeting of the American Association for the Study of Liver DiseasesSan Francisco 2011 Nov 6-9 |
 |
 |
 |
|
Wednesday, 23 November 2011 23:26 Written by Linda McInnes
|
|
This months American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) brought us new data on not only Victrelis (boceprevir) and Incivek (telaprevir), but also interim results on several all-oral regimens.
When the FDA approved both protease inhibitors, Victrelis and Incivek , the HCV community had a reason to celebrate. We finally had two drugs that offered shorter treatment duration with an increased SVR rate, finally a chance at curing the virus. Yes, it was time to usher in a new era of hepatitis C treatment.
The following AASLD summary attempts to present recent data in an accessible format providing a greater understanding of current and future gentler HCV therapies that could be available in the near future. Pharmasset for instance announced plans to seek U.S. and European approval in the second half of 2013 if the study results on their PSI-7977 all-oral regimen prove to be positive. A number of studies presented at the meeting on all-oral therapy demonstrated high cure rates, shorter treatment regimen and less side effects.
This summary is a collection of data from the latest medical news, clinical trial information, reports from the recent conference, news articles, Web searches, and links to other related sources on the Web relating to the recent liver meeting. Coverage from Medpage and NATAP our also included below.
*The data in this summary is considered to be preliminary until published in a peer-reviewed journal
Go to this link to view the article:
http://hepatitiscnewdrugresearch.com/aa ... eting.html
Add this page to your favourite Social Bookmarking websites;        
 
 |
